OpGen, Inc. (NASDAQ:OPGN) is reporting third quarter earnings results on Wednesday 11th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.36 per share.
For the full year, analysts predict revenues of $ 4.29 million, while looking forward to loss of $ 1.62 per share.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 1.00 million ~ $ 1.00 million
Click Here For More Historical Outlooks Of OpGen, Inc.
Previous Quarter Performance
OpGen, Inc. outlined loss for the second quarter of $ 0.49 per share, from the revenue of $ 1.19 million. The quarterly revenues boosted 17.82 percent compared with the same quarter last year. According to street consensus, OPGN was expected to report 2Q20 loss of $ 0.51 per share from revenue of $ 1.20 million. The bottom line results beat street analysts by $ 0.02 or 3.92 percent, at the same time, top line results fell short of analysts by $ 0.01 million or 0.83 percent.
Stock Performance
Shares of OpGen, Inc. traded up $ 0.03 or 1.42 percent on Tuesday, reaching $ 2.14 with volume of 291.30 thousand shares. OpGen, Inc. has traded high as $ 2.15 and has cracked $ 2.08 on the downward trend
The closing price of $ 2.14, representing a 129.35 % increase from the 52 week low of $ 0.92 and a 63.37 % decrease over the 52 week high of $ 5.76.
The company has a market capital of $ 42.37 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
OpGen, Inc. will be hosting a conference call at 4:30 PM eastern time on 11th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.opgen.com
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
